The price of Takeda Pharmaceutical Co ADR (NYSE: TAK) closed at $14.19 in the last session, down -1.39% from day before closing price of $14.39. On the day, 1714270 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
We take a closer look at TAK’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 21.77 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 12.78. For the most recent quarter (mrq), Quick Ratio is recorded 0.55 and its Current Ratio is at 1.06. In the meantime, Its Debt-to-Equity ratio is 0.69 whereas as Long-Term Debt/Eq ratio is at 0.64.
On July 19, 2022, Cowen Upgraded its rating to Outperform which previously was Market Perform and also upped its target price recommendation from $21 to $24.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 24 ’24 when TAKEDA PHARMACEUTICAL CO LTD sold 3,703,703 shares for $8.10 per share. The transaction valued at 29,999,994 led to the insider holds 3,755,583 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TAK now has a Market Capitalization of 45.43B and an Enterprise Value of 74.11B. As of this moment, Takeda’s Price-to-Earnings (P/E) ratio for their current fiscal year is 35.48, and their Forward P/E ratio for the next fiscal year is 30.03. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1774.19. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.50 while its Price-to-Book (P/B) ratio in mrq is 0.93. Its current Enterprise Value per Revenue stands at 0.02 whereas that against EBITDA is 0.07.
Stock Price History:
Over the past 52 weeks, TAK has reached a high of $17.15, while it has fallen to a 52-week low of $13.19. The 50-Day Moving Average of the stock is 14.52, while the 200-Day Moving Average is calculated to be 14.83.
Shares Statistics:
According to the various share statistics, TAK traded on average about 1.83M shares per day over the past 3-months and 1.71M shares per day over the past 10 days. A total of 3.14B shares are outstanding, with a floating share count of 3.14B. Insiders hold about 0.02% of the company’s shares, while institutions hold 5.45% stake in the company. Shares short for TAK as of Feb 29, 2024 were 6.26M with a Short Ratio of 3.01, compared to 7.54M on Jan 31, 2024.
Dividends & Splits
The forward annual dividend rate for TAK is 0.63, which was 184.00 in the trailing 12 months. Against a Trailing Annual Dividend Yield of 1,278.67%, it implies a Forward Annual Dividend Yield of 4.50%. The stock’s 5-year Average Dividend Yield is 4.71.
Earnings Estimates
The company has 0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0. EPS for the following year is $0, with 0 analysts recommending between $0 and $0.
